Premium
Peripheral CD 24 hi CD 27 + CD 19 + B cells subset as a potential biomarker in naïve systemic lupus erythematosus
Author(s) -
Jin Lin,
Weiqian Chen,
Lihuan Yue
Publication year - 2013
Publication title -
international journal of rheumatic diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.795
H-Index - 41
eISSN - 1756-185X
pISSN - 1756-1841
DOI - 10.1111/1756-185x.12229
Subject(s) - medicine , cd19 , cyclophosphamide , systemic lupus erythematosus , immunology , b cell , lupus erythematosus , regulatory b cells , flow cytometry , gastroenterology , antibody , chemotherapy , disease
Aim B cells are likely to play critical roles in the pathogenesis of systemic lupus erythematosus ( SLE ). Our aim was to investigate the role of peripheral CD 24 hi CD 27 + CD 19 + B cells in C hinese patients with new‐onset SLE . Method Peripheral CD 24 hi CD 27 + CD 19 + B cells were analyzed in 55 new‐onset lupus and 36 healthy controls by flow cytometry. All SLE cases were treated with prednisolone and hydroxychloroquine during a 1‐year follow‐up. Thirteen cases were added with cyclophosphamide or mycophenolate mofetil. The CD 24 hi CD 27 + CD 19 + B cells were analyzed at days 0, 7, 14 and months 1, 3, 6, 9 and 12. Interleukin‐10 ( IL ‐10)‐producing B cell was detected in eight naïve lupus and 10 healthy controls. Results Compared to healthy controls, the frequency and number of primary circulating CD 24 hi CD 27 + CD 19 + B cells was significantly reduced in SLE cases (8.22 ± 3.48% vs . 31.67 ± 5.53%, P < 0.0001; 4.04 ± 2.85 vs . 38.66 ± 10.22 10 3 cells/mL, P = 0.0001) before treatment; IL ‐10 + CD 19 + B cells and IL ‐10 + CD 24 hi CD 27 + CD 19 + B cells also decreased in SLE . Interestingly, primary CD 24 hi CD 27 + CD 19 + B cells inversely correlated with SLE disease activity index ( SLEDAI ) score. Patients with arthritis and hematologic disorders had a lower primary CD 24 hi CD 27 + CD 19 + B cells. In 48 SLE cases who finished the 1‐year follow‐up, the frequency and number of CD 24 hi CD 27 + CD 19 + B cells increased from 8.26 ± 3.61% to 25.51 ± 4.56%; 3.99 ± 2.86 to 28.64 ± 11.81 10 3 cells/mm 3 ( P < 0.0001), accompanied by a significantly decreased SLEDAI score. Of note, CD 24 hi CD 27 + CD 19 + B cells decreased in some flare cases with an elevated SLEDAI score. Conclusion These results demonstrate that a lower primary CD 24 hi CD 27 + CD 19 + B cells may be an immunologic aspect of new‐onset SLE . CD 24 hi CD 27 + CD 19 + B cells may be a useful tool to evaluate lupus activity and monitor the response to therapy.